Ultragenyx Non Current Liabilities Other from 2010 to 2024
| RARE Stock | USD 47.12 0.12 0.25% |
Non Current Liabilities Other | First Reported 2014-03-31 | Previous Quarter 15.2 M | Current Value 16.1 M | Quarterly Volatility 241 M |
Check Ultragenyx financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ultragenyx's main balance sheet or income statement drivers, such as Depreciation And Amortization of 27.3 M, Interest Expense of 69.3 M or Selling General Administrative of 325.3 M, as well as many indicators such as Price To Sales Ratio of 7.69, Dividend Yield of 0.0028 or PTB Ratio of 16.58. Ultragenyx financial statements analysis is a perfect complement when working with Ultragenyx Valuation or Volatility modules.
Ultragenyx | Non Current Liabilities Other |
Latest Ultragenyx's Non Current Liabilities Other Growth Pattern
Below is the plot of the Non Current Liabilities Other of Ultragenyx over the last few years. It is Ultragenyx's Non Current Liabilities Other historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Ultragenyx's overall financial position and show how it may be relating to other accounts over time.
| Non Current Liabilities Other | 10 Years Trend |
|
Non Current Liabilities Other |
| Timeline |
Ultragenyx Non Current Liabilities Other Regression Statistics
| Arithmetic Mean | 77,368,650 | |
| Geometric Mean | 5,409,749 | |
| Coefficient Of Variation | 196.69 | |
| Mean Deviation | 117,392,940 | |
| Median | 4,820,000 | |
| Standard Deviation | 152,174,143 | |
| Sample Variance | 23157T | |
| Range | 384.7M | |
| R-Value | 0.37 | |
| Mean Square Error | 21494T | |
| R-Squared | 0.14 | |
| Significance | 0.17 | |
| Slope | 12,645,740 | |
| Total Sum of Squares | 324197.6T |
Ultragenyx Non Current Liabilities Other History
About Ultragenyx Financial Statements
Ultragenyx stakeholders use historical fundamental indicators, such as Ultragenyx's Non Current Liabilities Other, to determine how well the company is positioned to perform in the future. Although Ultragenyx investors may analyze each financial statement separately, they are all interrelated. For example, changes in Ultragenyx's assets and liabilities are reflected in the revenues and expenses on Ultragenyx's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Ultragenyx. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Non Current Liabilities Other | 12.2 M | 11.6 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ultragenyx is a strong investment it is important to analyze Ultragenyx's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ultragenyx's future performance. For an informed investment choice regarding Ultragenyx Stock, refer to the following important reports:Check out the analysis of Ultragenyx Correlation against competitors. For information on how to trade Ultragenyx Stock refer to our How to Trade Ultragenyx Stock guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ultragenyx. If investors know Ultragenyx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ultragenyx listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.35) | Revenue Per Share 6.015 | Quarterly Revenue Growth 0.423 | Return On Assets (0.24) | Return On Equity (2.90) |
The market value of Ultragenyx is measured differently than its book value, which is the value of Ultragenyx that is recorded on the company's balance sheet. Investors also form their own opinion of Ultragenyx's value that differs from its market value or its book value, called intrinsic value, which is Ultragenyx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ultragenyx's market value can be influenced by many factors that don't directly affect Ultragenyx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ultragenyx's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ultragenyx is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ultragenyx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.